Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 16/20 | 0.40 |
| ▸ | CNR1 | P21554 | 15/20 | 0.40 |
| ▸ | FPR3 | P25089 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2538917 | 0.82 | NPC1 (0.41) | NPC1RAB9AKMT2A | |
| SCHEMBL6415380 | 0.81 | CNR2 (0.52) | CNR2CNR1NPC1RAB9AATM | |
| SCHEMBL17841457 | 0.80 | CNR2 (0.51) | CNR2CNR1KMT2A | |
| SCHEMBL13555791 | 0.77 | GRM5 (0.40) | CNR2CNR1NPC1RAB9AATM | |
| SCHEMBL22558685 | 0.76 | MAP4K4 (0.39) | CNR2CNR1NPC1RAB9AATM | |
| SCHEMBL6419777 | 0.75 | CNR2 (0.40) | CNR2CNR1NPC1RAB9AATM | |
| SCHEMBL13388126 | 0.75 | ADORA2A (0.40) | CNR2CNR1NPC1RAB9A | |
| SCHEMBL4240834 | 0.72 | OGG1 (0.53) | NPC1RAB9AATMKMT2A | |
| SCHEMBL658490 | 0.72 | CREBBP (0.41) | CNR1NPC1RAB9AKMT2A | |
| SCHEMBL930305 | 0.72 | P2RX7 (0.59) | NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936736-B2 | Amide derivative | SUMITOMO MANUFACTURING COMPANY LIMITED (JP) | 2005-08-30 | — | — | US | disclosed |
| US-20020147204-A1 | Amide derivative | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED | 2002-10-10 | — | — | US | disclosed |
| US-6384033-B1 | DRUGS FOR VISION DEFECTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147204-A1 | Amide derivative | ALDH1A2, NR1H2, HDAC3 | CNR2 183/4885CNR1 206/4885FPR3 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.